MLTX - Company ID 0001821586
MoonLake Immunotherapeutics trades as MLTX and has a market capitalization of $1.50 B, making it the #2357 largest US-listed company by market value. This page tracks MoonLake Immunotherapeutics through 296 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-11
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| Insider trade | 4 | 2026-05-13 |
| Quarterly report | 10-Q | 2026-05-11 |
| Major company event | 8-K | 2026-05-11 |
| Annual report to shareholders | ARS | 2026-04-21 |
| Proxy materials | DEFA14A | 2026-04-21 |
| Proxy statement | DEF 14A | 2026-04-21 |
| Insider trade | 4 | 2026-04-16 |
MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results | MoonLake Immunotherapeutics
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting | MoonLake Immunotherapeutics
MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results | MoonLake Immunotherapeutics
MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day | MoonLake Immunotherapeutics
MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day | MoonLake Immunotherapeutics
The largest companies sharing MoonLake Immunotherapeutics's SEC industry classification (pharmaceutical preparations).
MoonLake Immunotherapeutics (MLTX) has a market capitalization of $1.50 B as of 2026-07-11, ranking #2357 among US-listed companies.
In its latest fiscal year MoonLake Immunotherapeutics reported a net loss of $227.32M.